knowledge -WSS

knowledge

author：entertainment 2025-09-28 12:08:46 - browse：292

Photo illustration of Chris Viehbacher -- biotech coverage from STAT — Chris Viehbacher took over as Biogen CEO in November. Suzanne Kreiter/Globe staff; Photo illustration Alex Hogan/STAT

This was supposed to be the new Biogen. When Chris Viehbacher, a respected pharmaceutical executive, took over as CEO in November, Wall Street saw him as a steadying force for the wayward company and a strong personality who would stand up to its quarrelsome board.

Instead, Biogen’s board has saddled Viehbacher with the first crisis of his tenure at the company. Alex Denner, a long-time director, nominated a biotech executive who is also the mother of his child to succeed him on the board, and Biogen chose not to disclose the couple’s relationship to shareholders, an omission that shocked people close to the company and undermined the notion that Biogen was changing for the better.

“It’s just disappointing to see after all the criticism that has been levied at the company over the last few years, there really seems to be no self-awareness going into this recommendation,” said Brian Skorney, a securities analyst at Baird who covers Biogen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Data integrity in scientific journals requires "effort" by publishers, institutions

explore

WSS

Military medical care influenced by rank and race, new study finds

Nonprofit, backed by Microsoft, to certify AI tools in health care

Case highlights the risks of experimental stem cell therapy

Does Paxlovid work in people vaccinated against Covid

Hospital chaplains balance Covid safety with patients’ spiritual needs

When prostate cancer spreads, where it goes matters

hotspot

knowledge

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

Second House panel advances two

Virginia high school admissions case could be legal follow

Solving academic medical centers' existential crisis

Trump demands the U.S. pay no more for drugs than other countries … again

Boston Scientific acquires urology company Axonics for $3.7 billion

How to save PrEP access — and even expand it

FDA early review: GLP

Drug repurposing or repositioning? The language matters

Allen Institute goes after foundational questions, CEO Costa says

leisure time

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Case highlights the risks of experimental stem cell therapy

Second House panel advances two

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Hospital chaplains balance Covid safety with patients’ spiritual needs

focus

explore

hotspot

focus